Stockwinners Market Radar for November 12, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:06 EDT Box Office Battle: 'Thor: Ragnarok' wins weekend again with $56.6M - Disney (DIS) and Marvel Studios' "Thor: Ragnarok" won the weekend again with $56.6M for a 10-day domestic tally of $211.6M. Overseas, the movie also topped the chart with $75.9M for a foreign tally of $438.5M. The pic with Chris Hemsworth returning in the titular role earned 93% from Rotten Tomatoes. BOX OFFICE RUNNERS-UP: Paramount's (VIAB) "Daddy's Gome 2" came in second, taking in $30M over the weekend. Behind it was 20th Century Fox's (FOXA) "Murder on the Orient Express," opening with $28.2M from 3,341 theaters. "A Bad Moms Christmas" took number fourth, impressing in its second weekend as it grossed $11.5M for a domestic total of $39.4M. Rounding out the top five, Lionsgate's (LGF.A) "Jigsaw" earned $3.4M in its third week. Other publicly traded companies in filmmaking include Sony (SNE), Time Warner (TWX), and Comcast (CMCSA; CMCSK).

16:52 EDT Boeing, Azerbaijan Airlines announce deal for 787 Dreamliners, freighters - Boeing and Azerbaijan Airlines announced an order for five more 787-8 Dreamliners and a commitment to purchase two large freighters. The agreement, announced at the 2017 Dubai Air Show, is valued at about $1.9B at current list prices. The freighter commitment will be finalized at a later time. Azerbaijan Airlines also announced it will be the launch customer for the 787 Landing Gear Exchange Program whereby Boeing Global Services will provide the carrier with a lower-cost solution for overhauled and certified landing gears for its Dreamliner fleet, which now grows to seven airplanes.

16:45 EDT Navistar, Vietnam distributor sign MOU to export up to $1.8B in vehicles, parts - Navistar and Hoang Huy, its distributor in Vietnam, announced the signing of a memorandum of understanding paving the way for the export of up to $1.8B in International truck products into the Vietnamese market over the next ten years. The MOU represents the next phase of an already successful relationship between Navistar and Hoang Huy to grow its business in Vietnam over the next decade through the sale of new trucks, used trucks, and service parts.

16:37 EDT Honeywell signs 15-year maintenance, support agreement with Emirates - Honeywell (HON) has signed a 15-year Component Service Solutions agreement with Dubai-based Emirates to maintain aftermarket components on the airline's fleet of Airbus (EADSY) A380 and Boeing (BA) 777 aircraft. The technology used in this agreement extends through 2031 and covers comprehensive component repairs and support solutions for Emirates' fleet, thus reducing grounded aircraft time.

16:30 EDT First data for Nektar's 214/Bristol-Myers Opdivo combo revealed - Nektar (NKTR) and Bristol-Myers Squibb (BMY) announced the first presentation of data from the PIVOT-02 Phase 1/2 Study, which is designed to evaluate the combination of Bristol-Myers Squibb's Opdivo with Nektar's investigational medicine, NKTR-214. The initial results presented at the 2017 Society for Immunotherapy of Cancer Annual Meeting reported both safety and efficacy data for patients enrolled in the dose-escalation phase of the trial. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand and activate specific cancer-fighting T cells and natural killer cells directly in the tumor micro-environment and increase expression of cell-surface PD-1 on these immune cells. A total of 38 patients were enrolled in the dose-escalation phase of the ongoing PIVOT study in a number of dose cohorts. Responses were measured per RECIST 1.1 for efficacy-evaluable patients as of November 2, 2017.

16:12 EDT Alibaba generates $25.3B during Single's Day - Alibaba announced that $25.3B of gross merchandise volume was settled through Alipay on November 11, 2017, an increase of 39% compared to 2016. Mobile GMV settled through Alipay accounted for 90% of total GMV. "More than $25B of GMV in one day is not just a sales figure," said Daniel Zhang, CEO of Alibaba Group. "It represents the aspiration for quality consumption of the Chinese consumer, and it reflects how merchants and consumers alike have now fully embraced the integration of online and offline retail."

15:54 EDT Syndax announces presentation of immuno-oncology clinical trials data - Syndax (SNDX) Pharmaceuticals has announced results from the non-small cell lung cancer and melanoma cohorts of ENCORE 601, an open-label, Phase 1b/2 clinical trial employing a Simon two-stage design to evaluate the combination of entinostat, the company's class I selective HDAC inhibitor, plus Merck's (MRK) anti-PD-1 therapy, KEYTRUDA. In addition, data from the single ascending dose trial of SNDX-6352, the company's anti-CSF-1R monoclonal antibody, in healthy volunteers were presented at the Society of Immunotherapy of Cancer Annual Scientific Meeting being held November 8-12, 2017 in National Harbor, Maryland. According to shared data from the first stage of both NSCLC cohorts of ENCORE 601, the observed overall response rate was 10% in patients who had progressed on prior anti-PD-1 or PD-(L)1 therapy and 24% in patients naive to PD-1 or PD-(L)1 therapy. Across both NSCLC cohorts, the responders with known PD-(L)1 expression levels were all observed to be low or negative expressors. Three patients from each cohort remain on therapy, and two of the six have been on the combination for over one year. In addition to the NSCLC data, the poster, "Analysis of biomarkers from a cohort of advanced melanoma patients previously exposed to immune checkpoint inhibition treated with entinostat and pembrolizumab" containing updated data highlighting the clinical activity and novel translational research findings from the ENCORE 601 cohort of melanoma patients whose disease had progressed on prior PD-1 therapy was presented today. As of early September, four of 13 patients in this PD-1 refractory cohort remained on study, two of whom have received more than a year of the combination treatment. Pre-treatment tumor biopsies were obtained for all patients and matched post-treatment biopsies were available from nine patients. Gene expression, PD-1 and immunofluorescence analysis of tissue samples demonstrate that entinostat combined with KEYTRUDA may generate immune responsiveness in tumors previously resistant to immune checkpoint inhibition.